Dr. Reddy's launches semaglutide at ₹4,200/month: What's the catch

Obeda is as effective as Ozempic

Obeda passed a Phase III clinical trial with 312 participants, showing it's just as effective and safe as the original Ozempic for controlling blood sugar.
This gives people in India a reliable alternative without compromising on results.

Targeting middle-income groups in India and abroad

Obeda is made entirely in-house by Dr. Reddy's, especially for middle-income people outside big cities.

The company plans to introduce Obeda in multiple countries, subject to regulatory approvals.

More generic options coming soon

Other major pharmaceutical companies such as Sun Pharma, Zydus, Lupin, Cipla, Biocon, and MSN Laboratories are rolling out their own generic semaglutide soon, so expect diabetes treatment to get even more affordable across India.